This book provides a comprehensive overview of how use of micro- and nanotechnology (MNT) has allowed major new advance in vaccine development research, and the challenges that immunologists face in making further progress.
MNT allows the creation of particles that exploit the inherent ability of the human immune system to recognize small particles such as viruses and toxins. In combination with minimal protective epitope design, this permits the creation of immunogenic particles that stimulate a response against the targeted pathogen. The finely tuned response of the human immune system to small particles makes it unsurprising that many of the lead adjuvants and vaccine delivery systems currently under investigation are based on nanoparticles.
1. Introduction - p. xv 2. Chapter One: The Growing Influence of Nanotechnology in Our Lives - p. xviii 3. Chapter Two: Nanotechnology in Medical Research - p. 20 4. Chapter Three: Introduction to Vaccines and Vaccination - p. 45 5. Chapter Four: Overview of the Immune System - p. 62 6. Chapter Five: The Role of Antigen Presentation and Innate Immunity During Immune Induction by Particulate Antigens - p. 81 7. Chapter Six: Inflammatory/Noninflammatory Adjuvants and Nanotechnology—The Secret to Vaccine Design - p. 98 8. Abstract - p. 98 9. 6.1. Current Challenges Facing Vaccine Design - p. 99 10. 6.2. Inflammation: Angel or Devil? - p. 101 11. 6.3. Adjuvant Selection for Vaccine Design - p. 104 12. 6.4. Mechanisms of Conventional Adjuvants - p. 105 13. 6.5. Noninflammatory Adjuvants: Introducing Nanoparticles as Vaccine Adjuvants - p. 112 14. Summary - p. 117 15. Chapter Seven: Vaccine Adjuvant Nanotechnologies - p. 125 16. Chapter Eight: Nanoparticle-Based Peptide Vaccines - p. 147 17. Chapter Nine: Microparticles and Nanoparticles for Cancer-Targeting Vaccines - p. 170 18. Chapter Ten: Polymer-Based Nanoparticles as Modern Vaccine Delivery Systems - p. 183 19. Chapter Eleven: Virus-Like Particles - p. 203 20. Chapter Twelve: Liposomes as a Vaccine Delivery System - p. 219 21. Chapter Thirteen: Nanomaterials Based on Lipids for Vaccine Development - p. 239 22. Chapter Fourteen: Microparticles for Vaccine Delivery - p. 257 23. Chapter Fifteen: Nasal Vaccine Delivery - p. 278 24. Chapter Sixteen: Toward Mucosal DNA Delivery: Structural Modularity in Vaccine Platform Design - p. 301 25. Chapter Seventeen: Nano- and Microtechnology in Skin Delivery of Vaccines - p. 326 26. Chapter Eighteen: Nanopatches for Vaccine Delivery - p. 341 27. Chapter Nineteen: Rationale for Pulmonary Vaccine Delivery: Formulation and Device Considerations - p. 356 28. Chapter Twenty: Nanotoxicology and Nanovaccines - p. 371 29. Abstract - p. 371 30. 20.1. Introduction - p. 373 31. 20.2. General Toxicological Pathways for Nanoparticles - p. 374 32. 20.3. Acute and Chronic Toxicity - p. 379 33. 20.4. Toxicology of Nanovaccines - p. 382 34. 20.5. Concluding Remarks - p. 385 35. Chapter Twenty One: Regulatory Development of Nanotechnology-Based Vaccines - p. 392 36. Chapter Twenty Two: Commercial Aspects of Vaccine Development - p. 410 37. Subject Index - p. 421
This book provides a comprehensive overview of how use of micro- and nanotechnology (MNT) has allowed major new advance in vaccine development research, and the challenges that immunologists face in making further progress.
MNT allows the creation of particles that exploit the inherent ability of the human immune system to recognize small particles such as viruses and toxins. In combination with minimal protective epitope design, this permits the creation of immunogenic particles that stimulate a response against the targeted pathogen. The finely tuned response of the human immune system to small particles makes it unsurprising that many of the lead adjuvants and vaccine delivery systems currently under investigation are based on nanoparticles.
1. Introduction - p. xv 2. Chapter One: The Growing Influence of Nanotechnology in Our Lives - p. xviii 3. Chapter Two: Nanotechnology in Medical Research - p. 20 4. Chapter Three: Introduction to Vaccines and Vaccination - p. 45 5. Chapter Four: Overview of the Immune System - p. 62 6. Chapter Five: The Role of Antigen Presentation and Innate Immunity During Immune Induction by Particulate Antigens - p. 81 7. Chapter Six: Inflammatory/Noninflammatory Adjuvants and Nanotechnology—The Secret to Vaccine Design - p. 98 8. Abstract - p. 98 9. 6.1. Current Challenges Facing Vaccine Design - p. 99 10. 6.2. Inflammation: Angel or Devil? - p. 101 11. 6.3. Adjuvant Selection for Vaccine Design - p. 104 12. 6.4. Mechanisms of Conventional Adjuvants - p. 105 13. 6.5. Noninflammatory Adjuvants: Introducing Nanoparticles as Vaccine Adjuvants - p. 112 14. Summary - p. 117 15. Chapter Seven: Vaccine Adjuvant Nanotechnologies - p. 125 16. Chapter Eight: Nanoparticle-Based Peptide Vaccines - p. 147 17. Chapter Nine: Microparticles and Nanoparticles for Cancer-Targeting Vaccines - p. 170 18. Chapter Ten: Polymer-Based Nanoparticles as Modern Vaccine Delivery Systems - p. 183 19. Chapter Eleven: Virus-Like Particles - p. 203 20. Chapter Twelve: Liposomes as a Vaccine Delivery System - p. 219 21. Chapter Thirteen: Nanomaterials Based on Lipids for Vaccine Development - p. 239 22. Chapter Fourteen: Microparticles for Vaccine Delivery - p. 257 23. Chapter Fifteen: Nasal Vaccine Delivery - p. 278 24. Chapter Sixteen: Toward Mucosal DNA Delivery: Structural Modularity in Vaccine Platform Design - p. 301 25. Chapter Seventeen: Nano- and Microtechnology in Skin Delivery of Vaccines - p. 326 26. Chapter Eighteen: Nanopatches for Vaccine Delivery - p. 341 27. Chapter Nineteen: Rationale for Pulmonary Vaccine Delivery: Formulation and Device Considerations - p. 356 28. Chapter Twenty: Nanotoxicology and Nanovaccines - p. 371 29. Abstract - p. 371 30. 20.1. Introduction - p. 373 31. 20.2. General Toxicological Pathways for Nanoparticles - p. 374 32. 20.3. Acute and Chronic Toxicity - p. 379 33. 20.4. Toxicology of Nanovaccines - p. 382 34. 20.5. Concluding Remarks - p. 385 35. Chapter Twenty One: Regulatory Development of Nanotechnology-Based Vaccines - p. 392 36. Chapter Twenty Two: Commercial Aspects of Vaccine Development - p. 410 37. Subject Index - p. 421
